2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
An expert discusses updated overall survival results from the phase 2 PHAROS study evaluating encorafenib plus binimetinib in patients with BRAF V600E–mutant metastatic non–small cell lung cancer (mNSCLC).
Related Content: